Clinical Trials Logo

Clinical Trial Summary

Oral mucositis consequences can range from pain, decreased oral intake, impaired speech and swallowing to adverse events as severe as septicemia, increased hospitalization, and G-tube feeding A wide variety of agents have been tested to prevent OM or reduce its severity.This trial will assess the usefulness of solcoseryl and pumpkin seed oil versus Benzydamine Hydrochloride mouth wash in management of oral mucositis in patients receiving radiotherapy and/or chemotherapy.


Clinical Trial Description

The term "mucositis" was introduced to describe inflammation of the oral mucosa induced by radiotherapy, chemotherapy and bone marrow transplantation. At present, oral mucositis is considered to be the most serious non-hematological complication of cancer treatment. Numerous predisposing factors have been blamed for oral mucositis, including: the type of tumor involved, age of the patient, dental health, the nutritional condition of the patient, the maintenance of kidney and liver function and the type of cytostatic agent used. Clinically, oral Mucositis may appear as erythema, edema or ulceration that can be accompanied by alterations ranging from mild burning sensation to large and painful ulcers that wor¬sen patient's quality of life and limit basic oral functions such as speech, swallowing of saliva or eating. According to Multinational Association for Supportive Care in cancer and the International Society of Oral Oncology (MASCC/ISOO) guidelines for the management of mucositis, Management of oral mucositis is divided into the following sections: nutritional support, pain control, oral decontamination, palliation of dry mouth, management of oral bleeding and therapeutic interventions for oral mucositis. Since the primary symptom of oral mucositis is pain which significantly affects nutritional intake, mouth care and quality of life, thus, management of mucositis pain is a primary component of any mucositis management strategy. Use of saline mouth rinses, ice chips and topical mouthrinses containing an anesthetic such as 2% viscous lidocaine can help in reducing pain Based on the pathogenesis of mucositis with complex biological inflammatory pathways, various therapeutic approach have been proposed to improve oral mucositis. The current guidelines recommend the use of non-medicated oral rinses such as Benzydamine hydrochloride mouthwash and the use of short term pain killers. Benzydamine hydrochloride - which is a non-steroidal anti-inflammatory drug - can be used in the form of mouth rinse to reduce the severity of oral mucositis. Other management strategies include cryotherapy before the start of chemotheraputic agent administration and application of low-level laser therapy. Palifermin (Keratinocyte growth factor) is the only recommended preventive measure recommended by the ESMO Clinical Practice Guidelines. Solcoseryl, is a protein free standardized dialysate of calf blood extracted by ultrafiltration. The main constituents of Solcoseryl are inorganic electrolytes (chloride, phosphate, sodium, potassium, calcium, and magnesium) and low-molecular weight substances, including amino acids, biogenic amines and polyamines, sphingolipids, hexoses, eicosanoids, lactate, acetate, succinate, choline, vitamins, adenosine monophosphate (AMP) and inositol phospho-oligosaccharides. Solcoseryl has a number of beneficial effects. The most important of them include enhanced cellular glucose uptake, improvement of oxygen utilization and energy metabolism , neuroprotective effects, reduction of oxidative stress and apoptosis, accelerated wound healing and improvement of blood microcirculation. Pumpkin seed oils are good source of vitamins, minerals and anti-oxidants. Active components include fatty acid, 19.4% saturated fatty acids (palmitic acid and stearic acid), 80.7% unsaturated fatty acids (linoleic acid and oleic acid) , Tocopherol (β-tocopherol, γ-tocopherol, δ-tocopherol), carotenoids including β-carotene and lutein, Phytosterols or plant sterols, Amino acid Glutamic and aspartic acid, leucine, valine, phenylalanine, and tryptophan are among the amino acids identified. It has many therapeutic activities like antioxidant activity, anti inflammatory, antimicrobial activity, and anti carcinogenic effect. It is thus a good candidate to counteract the ongoing development of oral mucositis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04303312
Study type Interventional
Source Cairo University
Contact Ghada Zaki, Msc
Phone 01111122658
Email ghada.zaki@dentistry.cu.edu.eg
Status Not yet recruiting
Phase Phase 3
Start date December 2021
Completion date March 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT05331131 - Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial Phase 2
Not yet recruiting NCT06031012 - Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis Phase 3
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Recruiting NCT06217224 - Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma N/A
Completed NCT03416582 - Feasibility Study of a Nurse Intervention to Impact Mucositis Severity and Prevent Dehydration N/A
Completed NCT03577535 - Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients. Phase 2
Recruiting NCT04596410 - Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children N/A
Recruiting NCT05278260 - Hydrogen-rich Water and Treatment of Mucositis Caused by Radiation Therapy in Head and Neck Cancer Patients N/A
Recruiting NCT05308732 - Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy Phase 1
Completed NCT00293462 - GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Phase 3
Recruiting NCT05926297 - Treatment of Peri-implant Mucositis by Sodium Hypochlorite Gel and Cross-linked Hyaluronic Acid Gel N/A
Recruiting NCT05926557 - Treatment of Peri-implant Mucositis by Application of a Spermidine-based Gel N/A
Recruiting NCT04671862 - Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis N/A
Completed NCT04187222 - Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis Phase 3
Completed NCT05307445 - Treatment of Peri-Implant Mucositis With Standard of Care and Bioptron Hyperlight Therapy N/A
Completed NCT05214495 - Omega-3 Hydrogel and Prevention of Oral Mucositis Phase 2/Phase 3
Recruiting NCT03983369 - Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults Phase 3
Completed NCT06049511 - Oral Self Care Protocol and Oral Mucositis N/A
Not yet recruiting NCT05224882 - Chemotherapy Oral Manifestations and Dental Awareness Among Parents
Recruiting NCT03461354 - MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer N/A